Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II studyR. Gillis, N. Peled, I. Goldshtien, O. Rotem, A.B. Rozenblum, H. Nechushtan,L. Chen, E. Dudnik, A. Zer, S. Yust-Katz, I. Shelef,L.C. Roisman, E. InbarANNALS OF ONCOLOGY（2019）引用 0|浏览20暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
